Samir K Ballas

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6016099/publications.pdf

Version: 2024-02-01

185 papers	9,600 citations	53794 45 h-index	40979 93 g-index
187 all docs	187 docs citations	187 times ranked	5608 citing authors

#	Article	IF	Citations
1	Management of Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2014, 312, 1033.	7.4	1,189
2	Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease. New England Journal of Medicine, 2000, 342, 1855-1865.	27.0	1,062
3	Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia. JAMA - Journal of the American Medical Association, 2003, 289, 1645.	7.4	741
4	The risks and benefits of longâ€term use of hydroxyurea in sickle cell anemia: A 17.5 year followâ€up. American Journal of Hematology, 2010, 85, 403-408.	4.1	385
5	Sickle cell pain: a critical reappraisal. Blood, 2012, 120, 3647-3656.	1.4	333
6	Hydroxyurea and Sickle Cell Anemia Clinical Utility of a Myelosuppressive â€œSwitchingâ€•Agent. Medicine (United States), 1996, 75, 300-326.	1.0	294
7	Definitions of the phenotypic manifestations of sickle cell disease. American Journal of Hematology, 2010, 85, 6-13.	4.1	291
8	Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. American Journal of Hematology, 2005, 79, 17-25.	4.1	231
9	Purified Poloxamer 188 for Treatment of Acute Vaso-occlusive Crisis of Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2001, 286, 2099.	7.4	173
10	Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multiâ€center study of iron overload. American Journal of Hematology, 2007, 82, 255-265.	4.1	149
11	The role of blood rheology in sickle cell disease. Blood Reviews, 2016, 30, 111-118.	5.7	142
12	Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. American Journal of Hematology, 1989, 32, 104-111.	4.1	134
13	Pain Management of Sickle Cell Disease. Hematology/Oncology Clinics of North America, 2005, 19, 785-802.	2.2	134
14	Beyond the Definitions of the Phenotypic Complications of Sickle Cell Disease: An Update on Management. Scientific World Journal, The, 2012, 2012, 1-55.	2.1	125
15	Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes, 2006, 4, 59.	2.4	124
16	Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Seminars in Hematology, 2001, 38, 30-36.	3.4	121
17	Healthâ€related quality of life in adults with sickle cell disease (SCD): A report from the comprehensive sickle cell centers clinical trial consortium. American Journal of Hematology, 2011, 86, 203-205.	4.1	111
18	Current Issues in Sickle Cell Pain and Its Management. Hematology American Society of Hematology Education Program, 2007, 2007, 97-105.	2.5	97

#	Article	IF	Citations
19	Sickle Red Cell Microrheology and Sickle Blood Rheology. Microcirculation, 2004, 11, 209-225.	1.8	96
20	Exposure to Hydroxyurea and Pregnancy Outcomes in Patients With Sickle Cell Anemia. Journal of the National Medical Association, 2009, 101, 1046-1051.	0.8	94
21	The vasoâ€occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management. European Journal of Haematology, 2020, 105, 237-246.	2.2	92
22	Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. Transfusion, 2006, 46, 105-110.	1.6	89
23	Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Seminars in Hematology, 2001, 38, 30-36.	3.4	86
24	Sickle Cell Anaemia. Drugs, 2002, 62, 1143-1172.	10.9	84
25	The cost of health care for patients with sickle cell disease. American Journal of Hematology, 2009, 84, 320-322.	4.1	82
26	Sickle cell anemia with few painful crises is characterized by decreased red cell deformability and increased number of dense cells. American Journal of Hematology, 1991, 36, 122-130.	4.1	81
27	Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology, 2000, 64, 26-31.	4.1	77
28	More definitions in sickle cell disease: Steady state v base line data. American Journal of Hematology, 2012, 87, 338-338.	4.1	73
29	The Opioid Drug Epidemic and Sickle Cell Disease: Guilt by Association. Pain Medicine, 2016, 17, 1793-1798.	1.9	69
30	Molecular characteristics of pediatric patients with sickle cell anemia and stroke. American Journal of Hematology, 2001, 67, 179-182.	4.1	67
31	Reticulocyte Hemoglobin:An Integrated Parameter for Evaluation of Erythropoietic Activity. American Journal of Clinical Pathology, 1997, 108, 133-142.	0.7	66
32	Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology, 1999, 105, 491-496.	2.5	65
33	Hydroxyurea and Acute Painful Crises in Sickle Cell Anemia: Effects on Hospital Length of Stay and Opioid Utilization During Hospitalization, Outpatient Acute Care Contacts, and at Home. Journal of Pain and Symptom Management, 2010, 40, 870-882.	1.2	65
34	7 Sickle cell disease: clinical management. Best Practice and Research: Clinical Haematology, 1998, 11, 185-214.	1.1	61
35	Treatment of pain in adults with sickle cell disease. American Journal of Hematology, 1990, 34, 49-54.	4.1	60
36	Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: Effect of sex, age, and geographical location. American Journal of Hematology, 2010, 85, 613-616.	4.1	59

#	Article	IF	Citations
37	Hepatitis C in Sickle Cell Anemia. Journal of Clinical Gastroenterology, 1994, 18, 206-209.	2.2	56
38	l -arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency department. British Journal of Haematology, 2003, 120, 532-534.	2.5	55
39	Thinking beyond sickling to better understand pain in sickle cell disease. European Journal of Haematology, 2014, 93, 89-95.	2.2	53
40	The Prevalence of Avascular Necrosis in Sickle Cell Anemia: Correlation with Î±-Thalassemia. Hemoglobin, 1989, 13, 649-655.	0.8	51
41	Safety of Purified Poloxamer 188 in Sickle Cell Disease: Phase I Study of a Nonâ€ionic Surfactant in the Management of Acute Chest Syndrome. Hemoglobin, 2004, 28, 85-102.	0.8	49
42	Treatment of painful sickle cell leg ulcers with topical opioids. Blood, 2002, 99, 1096-1096.	1.4	48
43	Update on Pain Management in Sickle Cell Disease. Hemoglobin, 2011, 35, 520-529.	0.8	48
44	The diagnosis of pulmonary thromboembolism in sickle cell disease. American Journal of Hematology, 1979, 7, 219-232.	4.1	47
45	The effect of iron chelation therapy on overall survival in sickle cell disease and Î²â€thalassemia: A systematic review. American Journal of Hematology, 2018, 93, 943-952.	4.1	47
46	Newborn screening program for hemoglobinopathies in Rio de Janeiro, Brazil. Pediatric Blood and Cancer, 2014, 61, 34-39.	1.5	46
47	Hydroxyurea treatment does not increase blood viscosity and improves red blood cell rheology in sickle cell anemia. Haematologica, 2015, 100, e383-e386.	3.5	46
48	Sequential nitric oxide measurements during the emergency department treatment of acute vasoocclusive sickle cell crisis. , 2000, 64, 15-19.		44
49	Lactate dehydrogenase and hemolysis in sickle cell disease. Blood, 2013, 121, 243-244.	1.4	44
50	Climatic and geographic temporal patterns of pain in the Multicenter Study of Hydroxyurea. Pain, 2009, 146, 91-98.	4.2	43
51	Blood rheological abnormalities in sickle cell anemia. Clinical Hemorheology and Microcirculation, 2018, 68, 165-172.	1.7	38
52	Utilization of the office, hospital and emergency department for adult sickle cell patients: a five-year study. Journal of the National Medical Association, 2006, 98, 1109-13.	0.8	38
53	AAAPT Diagnostic Criteria for Acute Sickle Cell Disease Pain. Journal of Pain, 2019, 20, 746-759.	1.4	37
54	Greater erythrocyte deformability in world-class endurance athletes. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 276, H2188-H2193.	3.2	36

#	Article	IF	Citations
55	Viral Burden and Disease Progression in HIV-1â€“Infected Patients with Sickle Cell Anemia. American Journal of Hematology, 1998, 59, 199-207.	4.1	35
56	Morphine for the Treatment of Pain in Sickle Cell Disease. Scientific World Journal, The, 2015, 2015, 1-10.	2.1	35
57	BFU-E colony growth in response to hydroxyurea: Correlation between in vitro and in vivo fetal hemoglobin induction. , 1997, 56, 252-258.		34
58	Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1â€yr Phase 2 study. European Journal of Haematology, 2015, 95, 545-550.	2.2	34
59	Elevated serum and bronchoalveolar lavage fluid levels of interleukin 8 and granulocyte colony-stimulating factor associated with the acute chest syndrome in patients with sickle cell disease. British Journal of Haematology, 2000, 111, 482-490.	2.5	34
60	Non-pharmacologic Management of Sickle Cell Pain. Hematology, 2004, 9, 235-237.	1.5	33
61	Sickle cell disease: Classification of clinical complications and approaches to preventive and therapeutic management. Clinical Hemorheology and Microcirculation, 2018, 68, 105-128.	1.7	33
62	THE EVOLVING PHARMACOTHERAPEUTIC LANDSCAPE FOR THE TREATMENT OF SICKLE CELL DISEASE. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020010.	1.3	32
63	The Association Between Hydroxyurea Treatment and Pain Intensity, Analgesic Use, and Utilization in Ambulatory Sickle Cell Anemia Patients. Pain Medicine, 2011, 12, 697-705.	1.9	31
64	Safety and efficacy of blood exchange transfusion for priapism complicating sickle cell disease. Journal of Clinical Apheresis, 2016, 31, 5-10.	1.3	31
65	Pathophysiology and principles of management of the many faces of the acute vasoâ€occlusive crisis in patients with sickle cell disease. European Journal of Haematology, 2015, 95, 113-123.	2.2	29
66	Opioid utilization patterns in United States individuals with sickle cell disease. American Journal of Hematology, 2018, 93, E345-E347.	4.1	29
67	Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion, 2008, 48, 1971-1980.	1.6	28
68	Secretory Phospholipase A2Levels in Patients with Sickle Cell Disease and Acute Chest Syndrome. Hemoglobin, 2006, 30, 165-170.	0.8	27
69	The Impact of Hydroxyurea on Career and Employment of Patients With Sickle Cell Anemia. Journal of the National Medical Association, 2010, 102, 993-999.	0.8	27
70	Neuropathy, neuropathic pain, and sickle cell disease. American Journal of Hematology, 2013, 88, 927-929.	4.1	27
71	Mortality in children, adolescents and adults with sickle cell anemia in Rio de Janeiro, Brazil. Hematology, Transfusion and Cell Therapy, 2018, 40, 37-42.	0.2	26
72	Review/overview of pain in sickle cell disease. Complementary Therapies in Medicine, 2020, 49, 102327.	2.7	26

#	Article	IF	Citations
73	The Role of Nitric Oxide in Regulation of Red Blood Cell Deformability.. Blood, 2006, 108, 3730-3730.	1.4	26
74	Sickle cell disease: Current clinical management. Seminars in Hematology, 2001, 38, 307-314.	3.4	25
75	Red blood cell exchange: 2015 American Society for Apheresis consensus conference on the management of patients with sickle cell disease. Journal of Clinical Apheresis, 2017, 32, 342-367.	1.3	25
76	Erythrocyte glycophorin B deficiency may occur by two distinct gene alterations. American Journal of Hematology, 1991, 37, 57-58.	4.1	23
77	In vitro exposure to hydroxyurea reduces sickle red blood cell deformability. American Journal of Hematology, 2001, 67, 151-156.	4.1	22
78	High mortality among children with sickle cell anemia and overt stroke who discontinue blood transfusion after transition to an adult program. Transfusion, 2016, 56, 1014-1021.	1.6	22
79	Serum Immunoglobulin Levels in Patients Having Sickle Cell Syndromes. American Journal of Clinical Pathology, 1980, 73, 394-396.	0.7	21
80	Defining the Phenotypes of Sickle Cell Disease. Hemoglobin, 2011, 35, 511-519.	0.8	21
81	Original Research: A case-control genome-wide association study identifies genetic modifiers of fetal hemoglobin in sickle cell disease. Experimental Biology and Medicine, 2016, 241, 706-718.	2.4	21
82	Management of acute chest wall sickle cell pain with nebulized morphine. American Journal of Hematology, 2004, 76, 190-191.	4.1	20
83	Erythrocytes in Hb SC disease are microcytic and hyperchromic. American Journal of Hematology, 1988, 28, 37-39.	4.1	19
84	The Use of Cannabis by Patients with Sickle Cell Disease Increased the Frequency of Hospitalization due to Vaso-Occlusive Crises. Cannabis and Cannabinoid Research, 2017, 2, 197-201.	2.9	19
85	Rheological properties of sickle erythrocytes in patients with sickleâ€cell anemia: The effect of hydroxyurea, fetal hemoglobin, and Î±â€thalassemia. European Journal of Haematology, 2018, 101, 798-803.	2.2	19
86	Modified method of exchange transfusion in sickle cell disease. Journal of Clinical Apheresis, 1990, 5, 183-187.	1.3	18
87	Emerging drugs for sickle cell anemia. Expert Opinion on Emerging Drugs, 2015, 20, 47-61.	2.4	18
88	Deferiprone versus Deferoxamine in Sickle Cell Disease: Results from a 5-year long-term Italian multi-center randomized clinical trial. Blood Cells, Molecules, and Diseases, 2014, 53, 265-271.	1.4	17
89	Deep venous thrombosis in children with sickle cell disease. Pediatric Blood and Cancer, 2015, 62, 838-841.	1.5	17
90	Case series of octogenarians with sickle cell disease. Blood, 2016, 128, 2367-2369.	1.4	16

#	Article	IF	Citations
91	Plasmapheresis may improve clinical condition in sickle cell disease through its effects on red blood cell rheology. American Journal of Hematology, 2017, 92, E629-E630.	4.1	16
92	Predictors of impending acute chest syndrome in patients with sickle cell anaemia. Scientific Reports, 2020, 10, 2470.	3.3	15
93	Evaluation of Serum Immunoglobulins by Protein Electrophoresis and Rate Nephelometry Before and After Therapeutic Plasma Exchange. American Journal of Clinical Pathology, 1992, 98, 243-248.	0.7	14
94	Lack of Effect of Pentoxifylline on Red Blood Cell Deformability. Journal of Clinical Pharmacology, 1992, 32, 1050-1053.	2.0	14
95	Factitious sickle cell acute painful episodes: A secondary type of Munchausen syndrome. , 1996, 53, 254-258.		14
96	Effects of a Single Sickling Event on the Mechanical Fragility of Sickle Cell Trait Erythrocytes. Hemoglobin, 2010, 34, 24-36.	0.8	14
97	Alphaâ€thalassaemia and response to hydroxyurea in sickle cell anaemia. European Journal of Haematology, 2014, 92, 341-345.	2.2	14
98	Ethical issues in the management of sickle cell pain. American Journal of Hematology, 2001, 68, 127-132.	4.1	13
99	Meperidine for Acute Sickle Cell Pain in the Emergency Department: Revisited Controversy. Annals of Emergency Medicine, 2008, 51, 217.	0.6	13
100	Investigational drugs in sickle cell anemia. Expert Opinion on Investigational Drugs, 2009, 18, 1817-1828.	4.1	13
101	Comorbidities in aging patients with sickle cell disease. Clinical Hemorheology and Microcirculation, 2018, 68, 129-145.	1.7	13
102	Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults. The Cochrane Library, 2019, 2019, .	2.8	13
103	Erythrocyte Rh antigens increase with red cell age. American Journal of Hematology, 1986, 23, 19-24.	4.1	12
104	Treatment of the acute sickle cell vasoâ€occlusive crisis in the Emergency Department: a Brazilian method of switching from intravenous to oral morphine. European Journal of Haematology, 2014, 93, 34-40.	2.2	12
105	The Sixth Vital Sign: Body Mass Index in Patients With Sickle Cell Disease. Journal of Clinical Medicine Research, 2017, 9, 889-890.	1.2	12
106	Effect of Î±-Globin Genotype on the Pathophysiology of Sickle Cell Disease. Fetal and Pediatric Pathology, 2001, 20, 107-121.	0.3	11
107	Neonatal Screening for Sickle Cell Disease in a Metropolitan University Hospital: Efficacy and Problems. Journal of Medical Screening, 1994, 1, 229-232.	2.3	10
108	New era dawns on sickle cell pain. Blood, 2010, 116, 311-312.	1.4	10

#	Article	IF	Citations
109	Early Detection of Response to Hydroxyurea Therapy in Patients with Sickle Cell Anemia. Hemoglobin, 2010, 34, 424-429.	0.8	10
110	Neurocognitive Complications of Sickle Cell Anemia in Adults. JAMA - Journal of the American Medical Association, 2010, 303, 1862.	7.4	10
111	Leukapheresis for hyperviscosity. Transfusion, 1979, 19, 787-787.	1.6	9
112	Self-management of Sickle Cell Disease: A New Frontier. Journal of the National Medical Association, 2010, 102, 1042-1044.	0.8	9
113	Opioids and Sickle Cell Disease: From Opium to the Opioid Epidemic. Journal of Clinical Medicine, 2021, 10, 438.	2.4	9
114	Maternal and perinatal outcomes in pregnant women with sickle cell disease: an update. Hematology, Transfusion and Cell Therapy, 2022, 44, 369-373.	0.2	9
115	Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs. Journal of Medical Economics, 2013, 16, 10-18.	2.1	8
116	Deafness and Sickle Cell Disease: Three Case Reports and Review of the Literature. Journal of Clinical Medicine Research, 2015, 7, 189-192.	1.2	8
117	Perinatal Maternal Mortality in Sickle Cell Anemia: Two Case Reports and Review of the Literature. Hemoglobin, 2017, 41, 225-229.	0.8	8
118	Opioid Utilization by Pregnant Women with Sickle Cell Disease and the Risk of Neonatal Abstinence Syndrome. Journal of the National Medical Association, 2018, 110, 163-168.	0.8	8
119	Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease. The Cochrane Library, 2020, 2020, CD012762.	2.8	8
120	The impact of hydroxyurea on career and employment of patients with sickle cell anemia. Journal of the National Medical Association, 2010, 102, 993-9.	0.8	8
121	Stimulation of Lipid Synthesis in Reticulocytes as a Response to Membrane Damage. Blood, 1974, 44, 263-273.	1.4	7
122	FAILURE TO DEMONSTRATE RED CELL MEMBRANE PROTEIN ABNORMALITIES IN SICKLE CELL ANAEMIA. British Journal of Haematology, 1980, 46, 627-629.	2.5	7
123	The paradox of the serrated sickle erythrocyte: The importance of the red bloodÂcell membrane topography. Clinical Hemorheology and Microcirculation, 2016, 63, 149-152.	1.7	7
124	From total blood exchange to erythrocytapheresis and back to treat complications of sickle cell disease. Transfusion, 2017, 57, 2277-2280.	1.6	7
125	Time to rethink haemoglobin threshold guidelines in sickle cell disease. British Journal of Haematology, 2021, 195, 518-522.	2.5	7
126	Leg Amputation for an Extensive, Severe and Intractable Sickle Cell Anemia Ulcer in a Brazilian Patient. Hemoglobin, 2014, 38, 95-98.	0.8	6

#	Article	IF	Citations
127	Menopause in Brazilian women with sickle cell anemia with and without hydroxyurea therapy. Hematology, Transfusion and Cell Therapy, 2021, 43, 386-388.	0.2	6
128	Delayed hemolytic transfusion reaction in sickle cell anemia. Transfusion, 1980, 20, 477-477.	1.6	5
129	Folate supplementation and twinning in patients with sickle cell disease. American Journal of Hematology, 2006, 81, 296-297.	4.1	5
130	Sickle Cell Pain: Biology, Etiology, and Treatment. , 0, , 497-524.		5
131	Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults. The Cochrane Library, 0, , .	2.8	5
132	Randomized clinical trial of computerized PAINRelieveItÂ® for patients with sickle cell disease: PAINReportItÂ® and PAINUCopeÂ®. Patient Education and Counseling, 2020, 103, 136-144.	2.2	5
133	How I treat acute and persistent sickle cell pain. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020064.	1.3	5
134	Opioids are not a major cause of death of patients with sickle cell disease. Annals of Hematology, 2021, 100, 1133-1138.	1.8	5
135	Outcome of Transitioning Pediatric Patients with Sickle Cell Disease to Adult Programs.. Blood, 2004, 104, 3743-3743.	1.4	5
136	Risk Factors of Pulmonary Hypertension in Brazilian Patients with Sickle Cell Anemia. PLoS ONE, 2015, 10, e0137539.	2.5	5
137	Dental Complications of Sickle Cell Disease. JBR Journal of Interdisciplinary Medicine and Dental Science, 2014, 02, .	0.1	5
138	Molecular basis of asymptomatic Î²-thalassemia major in an African American individual. , 1997, 69, 196-199.		4
139	Characteristics of Acute Care Utilization of a Delaware Adult Sickle Cell Disease Patient Population. Population Health Management, 2014, 17, 60-65.	1.7	4
140	Amputations in Sickle Cell Disease: Case Series and Literature Review. Hemoglobin, 2016, 40, 150-155.	0.8	4
141	Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease. The Cochrane Library, 2017, , .	2.8	4
142	From Individualized Treatment of Sickle Cell Pain to Precision Medicine: A 40-Year Journey. Journal of Clinical Medicine Research, 2016, 8, 357-360.	1.2	4
143	Indications for RBC Exchange Transfusion in Patients with Sickle Cell Disease: Revisited. Annals of Clinical and Laboratory Science, 2019, 49, 836-837.	0.2	4
144	Hemoglobin Potomac: Clinical Picture, Biosynths and Stability. Hemoglobin, 1978, 2, 447-451.	0.8	3

#	Article	IF	Citations
145	Corticosteroids and Sickle Cell Disease. Journal of the National Medical Association, 2009, 101, 283.	0.8	3
146	Is the Medical Home for Adult Patients with Sickle Cell Disease a Reality or an Illusion?. Hemoglobin, 2015, 39, 130-133.	0.8	3
147	Treatment of dental complications in sickle cell disease. The Cochrane Library, 2019, 2019, CD011633.	2.8	3
148	Risk factors associated with increased emergency department utilization in patients with sickle cell disease: a systematic literature review. Annals of Hematology, 2020, 99, 2483-2495.	1.8	3
149	Definition of the Responder to Hydroxyurea Therapy: Revisited.. Blood, 2009, 114, 1513-1513.	1.4	3
150	Developmental Outcomes of Offspring of Adults Treated with Hydroxyurea in the Multicenter Study of Hydroxyurea.. Blood, 2009, 114, 1543-1543.	1.4	3
151	Impact of Hydroxyurea On Employment Among Patients with Sickle Cell Anemia.. Blood, 2009, 114, 2485-2485.	1.4	3
152	Patterns of Analgesic Utilization in the Multicenter Study of Hydroxyurea (MSH).. Blood, 2009, 114, 2577-2577.	1.4	3
153	Sickle Cell Genetic Markers: Geographic Distribution and Relation to Pain Outcomes in Multicenter Study of Hydroxyurea in Sickle Cell Anemia.. Blood, 2009, 114, 2582-2582.	1.4	3
154	Sickle Cell Disease and Pregnancy: Does Outcome Depend on Genotype or Phenotype?. International Journal of Clinical Medicine, 2011, 02, 313-317.	0.2	3
155	Hydration of sickle erythrocytes using a herbal extract (Pfaffia paniculata) in vitro. British Journal of Haematology, 2000, 111, 359-362.	2.5	2
156	Acute Chest Syndrome in Sickle Cell Anemia. Journal of Intensive Care Medicine, 2000, 15, 123-125.	2.8	2
157	Pfaffia paniculata extract improves red blood cell deformability in sickle cell patients. Clinical Hemorheology and Microcirculation, 2016, 62, 327-333.	1.7	2
158	Beyond the transition of adolescents and young adults with sickle cell disease to adult care: Role of geography. American Journal of Hematology, 2017, 92, E110-E112.	4.1	2
159	Of pools, oceans, and the Dead Sea. Blood, 2017, 130, 2578-2579.	1.4	2
160	Voxelotor Modulates the Analgesic Effect of Certain Opioids. Journal of Clinical Medicine Research, 2021, 13, 130-132.	1.2	2
161	Biosynthetic Evidence for Stability of Hb N-Baltimore. Hemoglobin, 1985, 9, 489-494.	0.8	1
162	Elevated serum and bronchoalveolar lavage fluid levels of interleukin 8 and granulocyte colonyâ€stimulating factor associated with the acute chest syndrome in patients with sickle cell disease. British Journal of Haematology, 2000, 111, 482-490.	2.5	1

#	Article	IF	Citations
163	Is Sickle Cell Disease a Hematologic Disorder?. Journal of the National Medical Association, 2012, 104, 463.	0.8	1
164	A predecessor of the current blood bank pneumatic tube delivery system. Transfusion, 2014, 54, 3035-3035.	1.6	1
165	Clinical Utility of Lactate Dehydrogenase in Determining the Severity of Hemolysis in Sickle Cell Anemia. American Journal of Clinical Pathology, 2015, 144, 173-174.	0.7	1
166	Comment on: negative health implications of sickle cell trait in high income countries: from the football field to the laboratory. British Journal of Haematology, 2016, 175, 349-350.	2.5	1
167	SURVIVAL PROBABILITY IN PATIENTS WITH SICKLE CELL ANEMIA USING THE COMPETITIVE RISK STATISTICAL MODEL. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019022.	1.3	1
168	Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology, 1999, 105, 491-496.	2.5	1
169	Sickle Red Cell Microrheology and Sickle Blood Rheology. Microcirculation, 2004, 11, 209-225.	1.8	1
170	Arginase Activity Is a Determinant of Nitric Oxide Levels in Adult Vasoocclusive Sickle Cell Crisis.. Blood, 2004, 104, 1670-1670.	1.4	1
171	Reply to â€˜Gender-specific disease modification by NOS3â€™. British Journal of Haematology, 2004, 126, 161-161.	2.5	0
172	The Dark Side of the Discovery of Sickle Cell Disease in the United States in 1910. Journal of the National Medical Association, 2010, 102, 1100-1101.	0.8	0
173	The first Cardeza donor center: attracting donors who do not wish to see blood. Transfusion, 2013, 53, 13-13.	1.6	0
174	Primary Stroke in a Woman With Sickle Cell Anemia Responsive to Hydroxyurea Therapy. Hemoglobin, 2014, 38, 373-375.	0.8	0
175	Case Series and Review of Hematological and Non-Hematological Malignancies in Aging Patients with Sickle Cell Disease in the Hydroxyurea Era. Hemoglobin, 2020, 44, 303-306.	0.8	0
176	Determinants of the Outcome of the Transition of Children with Sickle Cell Disease to Adult Programs. Hemoglobin, 2021, 45, 62-65.	0.8	0
177	Management of Severe Intractable Sickle Cell Pain with Intrathecal Opioid Analgesia.. Blood, 2004, 104, 3742-3742.	1.4	0
178	Folic Acid Supplementation and Twin Pregnancy in Patients with Sickle Cell Disease.. Blood, 2004, 104, 3744-3744.	1.4	0
179	Stroke in Sickle Cell Anemia After Excellent Response to Hydroxyurea.. Blood, 2009, 114, 4622-4622.	1.4	0
180	Footprints of Response to Hydroxyurea Are in the Hemogram.. Blood, 2009, 114, 4619-4619.	1.4	0

#	Article	IF	Citations
181	Sickle Cell Pain. , 2011, , 243-248.		0
182	Use of Marijuana in Patients with Sickle Cell Disease Increased the Frequency of Hospitalization for Acute Painful Vaso-Occlusive Crises. Blood, 2016, 128, 2498-2498.	1.4	0
183	Microglia-like Cells Derived from Hematopoietic Stem and Progenitor Cells Are a Model System to Investigate Chronic Pain in Sickle Cell Disease. Blood, 2018, 132, 1071-1071.	1.4	0
184	Defining Sickle Cell Disease Acute Painful Episodes: The Pisces Project. Blood, 2018, 132, 3510-3510.	1.4	0
185	Re-Assessing the Red Blood Cell Lifespan in Sickle Cell Anemia: Does Size Matter?. Blood, 2018, 132, 4877-4877.	1.4	0